Microneedle Flu Vaccine Market is Estimated to Witness High Growth...

Microneedle Flu Vaccine Market is Estimated to Witness High Growth Owing to its Efficient and Painless Delivery

Posted 2024-10-09 12:24:56

241

The microneedle flu vaccine market has grown significantly owing to the numerous advantages it offers over traditional flu vaccination methods. Microneedle vaccine patches consist of tiny needles made of dissolvable materials like polymer or sugar that deliver vaccination under the skin in a minimally invasive manner. These needles are nearly painless and can efficiently deliver the required dosage of vaccine within the epidermal and dermal skin layers. This novel delivery approach eliminates the need for trained healthcare professionals and sterile medical devices for vaccine administration.

The Global microneedle flu vaccine market is estimated to be valued at US$ 600 million in 2024 and is expected to exhibit a CAGR of 6.3% over the forecast period 2024-2031.

Key Takeaways

Key players: Key players operating in the microneedle flu vaccine market are Vaxxas, Raphas, and Visi vaccine.

Key opportunities: Increasing awareness about the benefits of pain-free vaccination and self-administration is expected to drive the demand for microneedle flu vaccines. Additionally, the rising focus on thermostable supply chain solutions for flu vaccination programs in developing regions offers lucrative growth opportunities.

Technological advancements: Advances in material sciences have led to the development of dissolvable microneedle patches made from novel polymers and sugar formulations that can deliver flu antigens effectively. 3D printing technologies are also being utilized to fabricate microneedles of precise sizes and shapes.

Market drivers

A key growth driver for the Microneedle Flu Vaccine Market Growth is the rising demand for thermostable and easy-to-administer flu vaccination solutions. Traditional syringe-based flu shots require strict temperature controls during transportation and storage, which adds complexity to mass immunization programs. In contrast, microneedle patches can maintain vaccine stability at temperatures upto 40°C for over 6 months, simplifying supply chain logistics.

Self-administration capability and painless delivery are other major factors driving preference for microneedle flu vaccines. This enables scaling up of flu vaccination coverage through decentralized distribution models.